Press release from Companies
Publicerat: 2020-05-27 08:56:04
Copenhagen, Denmark, May 27, 2020 – FluoGuide presents today as one of eight presenting companies at Orphan Drugs, an event hosted by Redeye.
Today, 27 May at 11:10 (CEST), FluoGuide’s CEO Morten Albrechtsen presents the company and some of the recent developments. The presentation is live broadcasted and can be followed at https://www.redeye.se/live/orphan-27-maj. For further information, please contact: About FluoGuide
Morten Albrechtsen, CEO
M: +45 24 25 62 66
ma@fluoguide.com
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, these improvements will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is planning a proof-of-concept clinical study (phase I/IIa) to demonstrate the effect of FG001 in patients with glioblastoma.
